From the guest editor: the evolving treatment paradigm in multiple myeloma.
Anderson
Kenneth C
KC
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D004317:Doxorubicin; D000077269:Lenalidomide